Back to search
Recurrent Diffuse Intrinsic Pontine Glioma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Diffuse Intrinsic Pontine Glioma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Diffuse Intrinsic Pontine Glioma trials you may qualify forThis phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous sy…
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a…
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS)…
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with n…
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Des…
A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or…
Although many children with brain tumours are successfully cured of their disease, a substantial proportion of patients suffer disease recurrence and require fu…